ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 973,75
0,45%
Dow Jones
38 711,29
0,36%
DAX
18 507,72
0,49%
Brent Oil
77,605
0,64%
Bitcoin
70 843,73
0,31%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) Actualités

OLMA

Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OLMA
DateHeureSourceTitreSymboleSociété
05/06/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
04/06/202422h28GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
04/06/202421h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
28/05/202413h03GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in JuneNASDAQ:OLMAOlema Pharmaceuticals Inc
15/05/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
15/05/202413h01GlobeNewswire Inc.Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422h02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202413h02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
01/05/202413h02GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in MayNASDAQ:OLMAOlema Pharmaceuticals Inc
08/04/202422h30GlobeNewswire Inc.Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421h03GlobeNewswire Inc.Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
06/03/202413h03GlobeNewswire Inc.Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsNASDAQ:OLMAOlema Pharmaceuticals Inc
14/02/202422h08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202423h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
06/02/202413h01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
31/01/202422h21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
08/01/202414h12GlobeNewswire Inc.Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development CandidateNASDAQ:OLMAOlema Pharmaceuticals Inc
05/01/202423h25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OLMAOlema Pharmaceuticals Inc
02/01/202422h01GlobeNewswire Inc.Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
08/12/202302h30Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
05/12/202318h27GlobeNewswire Inc.Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesNASDAQ:OLMAOlema Pharmaceuticals Inc
28/11/202323h10GlobeNewswire Inc.Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)NASDAQ:OLMAOlema Pharmaceuticals Inc
07/11/202322h02GlobeNewswire Inc.Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
01/11/202321h27GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in NovemberNASDAQ:OLMAOlema Pharmaceuticals Inc
22/10/202308h55GlobeNewswire Inc.Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for PalazestrantNASDAQ:OLMAOlema Pharmaceuticals Inc
18/10/202322h46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OLMA

Dernières Valeurs Consultées

BIT
GS0221
Goldman Sachs
LSE
37QB
Jsc Halyk 144a
OKEX
STARLUSDT
StarLink
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés